ClinicalTrials.Veeva

Menu

This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder

Pfizer logo

Pfizer

Status

Completed

Conditions

Overactive Bladder

Treatments

Behavioral: Your Way
Drug: Fesoterodine

Study type

Observational

Funder types

Industry

Identifiers

NCT00943735
A0221078

Details and patient eligibility

About

The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for fesoterodine.

Full description

This is a non-interventional, observational study. Study investigators will recruit symptomatic, fesoterodine-naïve subjects when they present with OAB symptoms during regularly-scheduled physician visits fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician visits

Enrollment

774 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female outpatients >=18 years old
  • Eligible for receiving Toviaz 4mg or 8mg QD treatment based on the approved US label.

Exclusion criteria

  • Female subjects who are pregnant, lactating, or who are intending to become pregnant within 28 days after the completion of the study (use of contraceptives is not required to participate in the study)
  • Have participated in any other studies involving study drugs within 30 days prior to entry in the study
  • Subjects who have previously taken fesoterodine.

Trial design

774 participants in 1 patient group

Fesoterodine arm
Description:
subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy
Treatment:
Behavioral: Your Way
Drug: Fesoterodine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems